Keros Therapeutics (KROS) is experiencing a significant decline in its stock price today following the announcement of a voluntary halt in dosing for two treatment arms in its Phase 2 TROPOS trial. The decision was made after a safety review revealed unanticipated pericardial effusion adverse events in the trial, which is evaluating cibotercept for pulmonary arterial hypertension. This development has raised concerns about the safety profile of the drug, leading to a negative market reaction.
Adding to the downward pressure, Keros Therapeutics faced a double blow from the investment community. H.C. Wainwright and Scotiabank both lowered their price targets for the company, with H.C. Wainwright slashing its target by $53 and Scotiabank by $33. These revisions reflect the increased uncertainty surrounding the company's lead product and its future prospects.
Keros Therapeutics' stock is currently trading at $17.65, down 4.23% from its previous close of $18.43, and has dropped 5.92% from its opening price of $18.76.